Bio-Techne Gets Access To B-MoGen Biotechnologies' Gene Editing Technology

Bio-Techne Corporation TECH and B-MoGen Biotechnologies, Inc. disclosed that Bio-Techne has made a seed investment in B-MoGen. The two have also have also struck a deal by which Bio-Techne would get access to gene editing technology.

Bio-Techne's CTO, Fernando Bazan, commented, "B-MoGen is a terrific investment in an emerging field of novel molecular and discovery tools that not only drives new science at a dizzying pace, but also provides a strong technological foundation for Bio-Techne to explore new generations of high-quality protein, antibody and cellular reagents, build innovative assays and instruments, and continue strongly as the leader in this life science field. We look forward to working closely with B-MoGen scientists."

Similarly, B-MoGen Biotechnologies CFO, Kristin Taylor Geisler, said, "We are pleased and excited to be working with Bio-Techne, and deploying our gene editing technology in an innovative effort to improve certain Bio-Techne products. While B-MoGen technology has tremendous therapeutic potential, we are just as interested in using the technology in products that enable life science research. The market reach of Bio-Techne will allow the benefits of B-MoGen gene editing to rapidly reach the broad market of researchers who rely on quality reagents to conduct their investigations."

Bio-Techne was excited to engage B-MoGen's unique expertise to explore the use of fresh gene editing technologies to continue enhancing the production, bioactivity and quality of their market-leading protein and antibody reagents.

On Tuesday, shares of the company traded 7.77 percent higher.